What is important to note about this is how few patients were needed to get to approval.
Belzutifan was investigated in the ongoing Study 004 (NCT03401788), an open-label clinical trial in 61 patients with VHL-associated RCC (VHL-RCC) diagnosed based on a VHL germline alteration and with at least one measurable solid tumor localized to the kidney. Enrolled patients had other VHL-associated tumors, including CNS hemangioblastomas and pNET. Patients received belzutifan 120 mg once daily until disease progression or unacceptable toxicity.
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-80
-
-
- There are more pages in this discussion • 1,768 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.64 |
Change
0.035(2.18%) |
Mkt cap ! $279.4M |
Open | High | Low | Value | Volume |
$1.61 | $1.66 | $1.61 | $96.41K | 58.73K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6109 | $1.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 460 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6109 | 1.635 |
2 | 6179 | 1.630 |
2 | 2388 | 1.625 |
3 | 8494 | 1.620 |
2 | 2085 | 1.615 |
Price($) | Vol. | No. |
---|---|---|
1.645 | 460 | 1 |
1.650 | 2124 | 2 |
1.655 | 4473 | 3 |
1.660 | 5000 | 1 |
1.665 | 1384 | 2 |
Last trade - 11.25am 29/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |